In published preclinical studies in primates, sobetirome has been shown to lower LDL cholesterol and Lp(a) and to promote weight loss. Lp(a) is a lipoprotein that is associated with an increased risk of stroke and coronary heart disease. In preclinical studies in mice, sobetirome also stimulated steps of reverse cholesterol transport. This process involves the transport of cholesterol from peripheral tissues to the liver for conversion into bile acids and then excretion from the body.
LDL Cholesterol, Cardiovascular Disease and Current Treatments
High LDL cholesterol levels have been shown to increase the risk of
cardiovascular disease including coronary heart disease and stroke.
Approximately 70 million Americans have some form of cardiovascular
disease, according to the American Heart Association. Lowering LDL
cholesterol to reduce cardiovascular risk is a primary focus of currently
available lipid regulating therapies, of which statins are the most
frequently prescribed class. While statins have been shown to lower LDL
levels in many people with high LDL cholesterol, some patients are unable
to tolerate statins due to side effects and many others fail to reach their
LDL treatment targets in treatment involving statins alone. In addition, a
substantial number of patients with elevated LDL levels also have other
cardiovascular risk factors such as obesity, high Lp(a) and high
triglycerides, which are not adequately addressed by statin therapy. In all
of these sizable patient sub-populations, there is a need for new treatment
|SOURCE QuatRx Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved